|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCL11 |
Gene summary for CCL11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCL11 | Gene ID | 6356 |
| Gene name | C-C motif chemokine ligand 11 | |
| Gene Alias | SCYA11 | |
| Cytomap | 17q12 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P51671 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6356 | CCL11 | P4T-E | Human | Esophagus | ESCC | 3.30e-03 | 9.21e-01 | 0.1323 |
| 6356 | CCL11 | P9T-E | Human | Esophagus | ESCC | 6.80e-05 | 1.49e+00 | 0.1131 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
| GO:0031334111 | Esophagus | ESCC | positive regulation of protein-containing complex assembly | 166/8552 | 237/18723 | 2.06e-14 | 1.07e-12 | 166 |
| GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
| GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:1902905111 | Esophagus | ESCC | positive regulation of supramolecular fiber organization | 142/8552 | 209/18723 | 5.51e-11 | 1.76e-09 | 142 |
| GO:1902903111 | Esophagus | ESCC | regulation of supramolecular fiber organization | 237/8552 | 383/18723 | 9.06e-11 | 2.75e-09 | 237 |
| GO:005149520 | Esophagus | ESCC | positive regulation of cytoskeleton organization | 147/8552 | 226/18723 | 2.93e-09 | 6.38e-08 | 147 |
| GO:0051258111 | Esophagus | ESCC | protein polymerization | 183/8552 | 297/18723 | 1.94e-08 | 3.75e-07 | 183 |
| GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
| GO:0032273111 | Esophagus | ESCC | positive regulation of protein polymerization | 95/8552 | 138/18723 | 2.97e-08 | 5.57e-07 | 95 |
| GO:003253520 | Esophagus | ESCC | regulation of cellular component size | 227/8552 | 383/18723 | 4.77e-08 | 8.60e-07 | 227 |
| GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:0032970111 | Esophagus | ESCC | regulation of actin filament-based process | 231/8552 | 397/18723 | 2.91e-07 | 4.20e-06 | 231 |
| GO:0032956111 | Esophagus | ESCC | regulation of actin cytoskeleton organization | 210/8552 | 358/18723 | 4.40e-07 | 6.00e-06 | 210 |
| GO:0032271111 | Esophagus | ESCC | regulation of protein polymerization | 143/8552 | 233/18723 | 9.21e-07 | 1.17e-05 | 143 |
| GO:011005327 | Esophagus | ESCC | regulation of actin filament organization | 166/8552 | 278/18723 | 1.54e-06 | 1.85e-05 | 166 |
| GO:002260420 | Esophagus | ESCC | regulation of cell morphogenesis | 180/8552 | 309/18723 | 5.19e-06 | 5.45e-05 | 180 |
| GO:002261216 | Esophagus | ESCC | gland morphogenesis | 78/8552 | 118/18723 | 5.83e-06 | 6.03e-05 | 78 |
| GO:006056210 | Esophagus | ESCC | epithelial tube morphogenesis | 187/8552 | 325/18723 | 9.95e-06 | 9.44e-05 | 187 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0465727 | Esophagus | ESCC | IL-17 signaling pathway | 66/4205 | 94/8465 | 3.93e-05 | 1.75e-04 | 8.99e-05 | 66 |
| hsa0465734 | Esophagus | ESCC | IL-17 signaling pathway | 66/4205 | 94/8465 | 3.93e-05 | 1.75e-04 | 8.99e-05 | 66 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| CCL11 | ACKR1 | CCL11_ACKR1 | CCL | CRC | AD |
| CCL11 | ACKR1 | CCL11_ACKR1 | CCL | CRC | SER |
| CCL11 | ACKR1 | CCL11_ACKR1 | CCL | Esophagus | ESCC |
| CCL11 | ACKR2 | CCL11_ACKR2 | CCL | Esophagus | ESCC |
| CCL11 | ACKR1 | CCL11_ACKR1 | CCL | GC | ADJ |
| CCL11 | ACKR1 | CCL11_ACKR1 | CCL | GC | GC |
| CCL11 | ACKR1 | CCL11_ACKR1 | CCL | GC | Healthy |
| CCL11 | ACKR1 | CCL11_ACKR1 | CCL | HNSCC | OSCC |
| CCL11 | ACKR2 | CCL11_ACKR2 | CCL | HNSCC | OSCC |
| CCL11 | ACKR1 | CCL11_ACKR1 | CCL | HNSCC | Precancer |
| CCL11 | ACKR2 | CCL11_ACKR2 | CCL | HNSCC | Precancer |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCL11 | SNV | Missense_Mutation | novel | c.247N>T | p.Asp83Tyr | p.D83Y | P51671 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| CCL11 | SNV | Missense_Mutation | rs779102512 | c.211N>A | p.Asp71Asn | p.D71N | P51671 | protein_coding | deleterious(0.02) | benign(0.281) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCL11 | SNV | Missense_Mutation | novel | c.194N>C | p.Lys65Thr | p.K65T | P51671 | protein_coding | tolerated(0.07) | benign(0.248) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| CCL11 | SNV | Missense_Mutation | novel | c.122N>G | p.Ile41Arg | p.I41R | P51671 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCL11 | SNV | Missense_Mutation | novel | c.22N>A | p.Leu8Met | p.L8M | P51671 | protein_coding | deleterious(0.01) | probably_damaging(0.973) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| CCL11 | SNV | Missense_Mutation | novel | c.116N>T | p.Arg39Met | p.R39M | P51671 | protein_coding | deleterious(0.01) | possibly_damaging(0.653) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| CCL11 | SNV | Missense_Mutation | novel | c.14N>T | p.Ala5Val | p.A5V | P51671 | protein_coding | tolerated(0.17) | benign(0.027) | TCGA-AX-A2IN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| CCL11 | SNV | Missense_Mutation | novel | c.164G>A | p.Gly55Asp | p.G55D | P51671 | protein_coding | deleterious(0) | benign(0.216) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCL11 | SNV | Missense_Mutation | c.55N>A | p.Pro19Thr | p.P19T | P51671 | protein_coding | tolerated(1) | benign(0.003) | TCGA-UB-A7MB-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sorafenib | PD | |
| CCL11 | SNV | Missense_Mutation | c.127N>G | p.Leu43Val | p.L43V | P51671 | protein_coding | tolerated(0.61) | benign(0.05) | TCGA-69-7980-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6356 | CCL11 | DRUGGABLE GENOME | TNF-ALPHA | 15972682 | ||
| 6356 | CCL11 | DRUGGABLE GENOME | inhibitor | CHEMBL2109103 | BERTILIMUMAB | |
| 6356 | CCL11 | DRUGGABLE GENOME | ROXITHROMYCIN | ROXITHROMYCIN | 11408771 | |
| 6356 | CCL11 | DRUGGABLE GENOME | methadone | METHADONE | 29222992 | |
| 6356 | CCL11 | DRUGGABLE GENOME | MOMETASONE FUROATE | 12877820 | ||
| 6356 | CCL11 | DRUGGABLE GENOME | TYROSINE KINASE INHIBITOR | 10527858 | ||
| 6356 | CCL11 | DRUGGABLE GENOME | Bertilimumab | BERTILIMUMAB |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |